At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LEGN Legend Biotech
Trading 12-11 15:10:26 EST
23.07
-0.29
-1.24%
High23.55Low23.02Vol1.03M
Open23.45D1 Closing23.36Amplitude2.26%
Mkt Cap4.26BTradable Cap1.88BTotal Shares184.69M
T/O23.82MT/O Rate1.26%Tradable Shares81.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says
MT Newswires Live  ·  12-11 01:03
Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says
Cancer Study Buoys These Small Biotechs -- Barrons.com
Dow Jones  ·  12-10 04:31
Cancer Study Buoys These Small Biotechs -- Barrons.com
HK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight
Stock News  ·  12-09 14:04
HK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight
Legend Biotech Is Maintained at Buy by UBS
Dow Jones  ·  12-08
Legend Biotech Is Maintained at Buy by UBS
UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating
MT Newswires Live  ·  12-08
UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating
Legend Biotech Reports CARVYKTI® Delivers Median PFS of 50.4 Months in Multiple Myeloma Trial
Reuters  ·  12-08
Legend Biotech Reports CARVYKTI® Delivers Median PFS of 50.4 Months in Multiple Myeloma Trial
GenScript Affiliate Legend Biotech Showcases CAR-T Data at 2025 ASH Meeting
Reuters  ·  12-07
GenScript Affiliate Legend Biotech Showcases CAR-T Data at 2025 ASH Meeting
BRIEF-Legend Biotech Highlights New Carvykti® Data In Multiple Myeloma And First-In-Human Results From Novel Car-T Platform In Non-Hodgkin Lymphoma At Ash 2025
Reuters  ·  12-07
BRIEF-Legend Biotech Highlights New Carvykti® Data In Multiple Myeloma And First-In-Human Results From Novel Car-T Platform In Non-Hodgkin Lymphoma At Ash 2025
Legend Biotech Highlights New Carvykti® Data in Multiple Myeloma and First-in-Human Results From Novel CAR-T Platform in Non-Hodgkin Lymphoma at Ash 2025
THOMSON REUTERS  ·  12-07
Legend Biotech Highlights New Carvykti® Data in Multiple Myeloma and First-in-Human Results From Novel CAR-T Platform in Non-Hodgkin Lymphoma at Ash 2025
Legend Biotech Reports CARVYKTI Achieves 50.4-Month Median PFS in Multiple Myeloma Trial
Reuters  ·  12-07
Legend Biotech Reports CARVYKTI Achieves 50.4-Month Median PFS in Multiple Myeloma Trial
Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
GlobeNewswire  ·  11-27
Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade
Final Victory in Court! Former Legend Biotech Executive: A Triumph for Justice
Deep News  ·  11-20
Final Victory in Court! Former Legend Biotech Executive: A Triumph for Justice
Why Genscript Biotech (SEHK:1548) Is Up 8.0% After Legend Biotech’s CARVYKTI Drives Smaller Q3 Loss
Simply Wall St.  ·  11-15
Why Genscript Biotech (SEHK:1548) Is Up 8.0% After Legend Biotech’s CARVYKTI Drives Smaller Q3 Loss
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
GlobeNewswire  ·  11-14
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)
TIPRANKS  ·  11-13
Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Legend Biotech Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones  ·  11-13
Legend Biotech Is Maintained at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Sticks to Their Buy Rating for Legend Biotech (LEGN)
TIPRANKS  ·  11-13
Cantor Fitzgerald Sticks to Their Buy Rating for Legend Biotech (LEGN)
Legend Biotech : Barclays Cuts Target Price to $90 From $94
THOMSON REUTERS  ·  11-13
Legend Biotech : Barclays Cuts Target Price to $90 From $94
Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating
MT Newswires Live  ·  11-13
Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating
Legend Biotech Corp : Truist Securities Cuts Target Price to $70 From $71
THOMSON REUTERS  ·  11-13
Legend Biotech Corp : Truist Securities Cuts Target Price to $70 From $71

Introduction

Company Name.
Legend Biotech
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Legend Biotech Corp is a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's differentiated technology, global development and manufacturing strategy and expertise provide it with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.
Issue price:
--